Trial · NCT05015595
Memantine for Refractory OCD Patients
NCT05015595, Phase 3, Unknown, University of Roma La Sapienza
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Memantine for Refractory OCD Patients. Trials, record NCT05015595. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05015595
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Memantine for Refractory OCD Patients
- NCT number
- NCT05015595
- Status
- Unknown
- Phases
- Phase 3
- Enrollment
- 20 participants, estimated
- Lead sponsor
- University of Roma La Sapienza
- Conditions
- Obsessive-Compulsive Disorder
- Interventions
- Memantine Oral Tablet, Placebo
- First posted
- 2021-08-20
- Last updated
- 2021-08-20
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Improvement of OCD symptoms will be intended as a rate of more then 1/3 on the Y-BOCS total score. | From the week number 5 to the week number 52 | The investigators will evaluate the improvement of symptoms through a decrease of OCD, intended as a rate of more then 1/3 on the Y-BOCS total score. |
| Secondary | Evaluate the minimum effective dose of memantine | From the week number 5 to the week number 46 | The second aim of the study is to evaluate the minimum effective dose of memantine in these patients. The investigators will evaluate the improvement of symptoms through reduction of both subscales (obsessive thoughts and compulsive behaviors) and of the total Y-BOCS score. |
| Secondary | Evaluate the effects after drug withdrawal through follow up | From the week number 5 to the week number 46 | Moreover the investigators will evaluate the effects after drug withdrawal during follow up through reduction of both subscales (obsessive thoughts and compulsive behaviors) and of the total Y-BOCS score. |
| Other | Improvement at the WAIS-IV. | from the week number 5 to the week number 52 | The third aim is to investigate the effect of memantine on patients without cognitive impairment, on improvement of cognitive functions through the reduction of total score of the WAIS-IV Digit Symbol. |
| Other | Improvement at the Trial Making Test. | from the week number 5 to the week number 52 | The fourth aim is to evaluate the effect of memantine on patients without cognitive impairment, on improvement of cognitive functions through the reduction of total score of the Trial Making Test. |
| Other | Improvement at the Digit and Corsi Span. | from the week number 5 to the week number 52 | The fifth aim is to evaluate the effect of memantine on patients without cognitive impairment, on improvement of cognitive functions through the reduction of total score of the Digit and Corsi Span. |
| Other | Improvement at the Corsi Block Tapping test. | from the week number 5 to the week number 52 | The sixth aim is to evaluate the effect of memantine on patients without cognitive impairment, on improvement of cognitive functions through the reduction of total score of the Corsi Block Tapping test. |
| Other | Improvement at the Story recall of Rivermead Behavioral Memory Test. | from the week number 5 to the week number 52 | The sixth aim is to evaluate the effect of memantine on patients without cognitive impairment, on improvement of cognitive functions through the reduction of total score of the Story recall of Rivermead Behavioral Memory Test. |
| Other | Improvement at the Babcock Story recall test. | from the week number 5 to the week number 52 | The eighth aim is to evaluate the effect of memantine on patients without cognitive impairment, on improvement of cognitive functions through the reduction of total score of the Story recall of Babcock Story recall test. |
| Other | Improvement at the Stroop Task. | from the week number 5 to the week number 52 | The ninth aim is to evaluate the effect of memantine on patients without cognitive impairment, on improvement of cognitive functions through the reduction of total score of the Stroop Task. |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers25
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests4
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Corsi Block-Tapping Test | Other outcome | ConductCognition |
| Short Story Recall | Other outcome | ConductCognition |
| Stroop Color-Word Test | Other outcome | ConductCognition |
| Tower Planning | Other outcome | ConductCognition |
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05015595
GET https://conductscience.org/api/trials/v1/NCT05015595/papers?page=2